TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8708979
Drug: Liquid Gaviscon
Normalized name: Gaviscon Oral Liquid Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid Gaviscon (20 mL single dose)
Study: 8708979
Drug: Algitec Suspension
Normalized name: Algitec
Approvals — FDA: no, EMA: no, PMDA: no
Description: Algitec Suspension (20 mL single dose)
Study: 8708979
Drug: Algitec Suspension
Normalized name: Algitec
Approvals — FDA: no, EMA: no, PMDA: no
Description: Algitec Suspension
Study: 1907317
Drug: APDT vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: APDT vaccine
Study: 12677622
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg of IV lidocaine (group L)
Study: 12677622
Drug: 0.1 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mL/kg of IV isotonic saline (group C)
Study: 8400327
Drug: High levels
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High levels of tumour cyclic AMP binding proteins (> 8 pmol/mg cytosol protein)
Study: 29669668
Drug: GSP301 (olopatadine
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSP301 (olopatadine 665 μg - mometasone 50 μg)
Study: 29669667
Drug: OLO-sponsor (olopatadine
Approvals — FDA: no, EMA: no, PMDA: no
Description: OLO-sponsor (olopatadine 665 μg)
Study: 29669667
Drug: OLO (FDA
Approvals — FDA: no, EMA: no, PMDA: no
Description: OLO (FDA approved olopatadine 665 μg)
Study: 7811150
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of delayed action mexiletine
Study: 3658285
Drug: 25-mg 17
Normalized name: ubidecarenone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25-mg 17 beta-estradiol pellets
Study: 3658285
Drug: 50-mg 17
Normalized name: azathioprine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50-mg 17 beta-estradiol pellets
Study: 3658285
Drug: 25-mg and
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25-mg and 50-mg 17 beta-estradiol pellets
Study: 31317627
Drug: 4 mL
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mL of 75% oral sucrose (n = 20)
Study: 29068099
Drug: Ciclosporin 50
Normalized name: Ciclosporin 50 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclosporin 50 mg/mL solution for injection administered subcutaneously for 60 days, with initial doses ranging from 2.5 mg/kg once daily to every other day, and 5 mg/kg once daily to every other day.
Study: 27484224
Drug: Iloprost (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iloprost (1 ng/kg/min) infusion for 48 hours
Study: 25400947
Drug: Celecoxib 100
Normalized name: celecoxib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 100 mg orally every 12 hours for at least 2 days
Study: 21168619
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of cyclosporine (blood cyclosporine C2, 800-1500 ng/mL) with MMF and standard doses of corticosteroids.
Study: 21168619
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of cyclosporine (blood cyclosporine C2, 450-800 ng/mL) with MMF plus low doses of corticosteroids after induction 48 hours before surgery.
Study: 16725396
Drug: Calcium-vitamin-D3-fortified milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-vitamin-D3-fortified milk (1000 mg/day calcium and 800 IU/day vitamin D3)
Study: 11040177
Drug: Methylprednisolone (0.75‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (0.75‐1 mg x kg(‐1) x day(‐1))
Study: 11040177
Drug: Heparin (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (continuous infusion)
Study: 1350734
Drug: Polyanhydrides as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyanhydrides as bioerodible polymers for drug delivery applications
Study: 1350734
Drug: Polyanhydride-based drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyanhydride-based drug delivery treatment
Study: 2981616
Drug: Levonantradol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonantradol (1 mg every 4 hours)
Study: 2981616
Drug: Delta-9-tetrahydrocannabinol (THC)
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delta-9-tetrahydrocannabinol (THC) (15 mg every 4 hours)
Study: 15753149
Drug: Selenium (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium (200 mcg l-selenomethionine)
Study: 15753149
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (400 mg of racemic alpha-tocopheryl)
Study: 11728984
Drug: EPO 50
Normalized name: Evening Primrose Oil 500 MG Oral Capsule, Liquid Filled [NUTR-EPO 500]
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPO 50 U/kg by subcutaneous injection 3 times per week
Study: 11728984
Drug: EPO 50
Normalized name: Evening Primrose Oil 500 MG Oral Capsule, Liquid Filled [NUTR-EPO 500]
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPO 50 U/kg IV injection and AG 200 mg every other day by mouth
Study: 11728984
Drug: EPO 50
Normalized name: Evening Primrose Oil 500 MG Oral Capsule, Liquid Filled [NUTR-EPO 500]
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPO 50 U/kg IV injection and placebo
Study: 8150356
Drug: Pre-oxygenation with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-oxygenation with 4 litres/minute for five minutes before sedation, followed by continuous oxygen administration.
Study: 27166718
Drug: 25 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 μg of hCG, intravenously
Study: 25429036
Drug: Immediate therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate therapy (scaling and root planing, oral hygiene instruction, chlorhexidine rinse)
Study: 25429036
Drug: Delayed therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed therapy (scaling and root planing, oral hygiene instruction, chlorhexidine rinse)
Study: 23692648
Drug: Multifactorial intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multifactorial intervention consisting of sessions concerning sports, parental involvement, individual counselling, lifestyle advice including dietary advice and cognitive behavioural therapy for 18 months.
Study: 20673506
Drug: BSD2000 deep
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: BSD2000 deep hyperthermia combined with chemotherapy (paclitaxel: 135 mg/m2 ivdirp 3 h qd d1 + cisplatin: 20 mg/m2 ivdirp qd d1-5)
Study: 20673506
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (paclitaxel and cisplatin)
Study: 14661009
Drug: Candesartan 4
Normalized name: candesartan 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 4 mg/d
Study: 14661009
Drug: Control (baseline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (baseline treatment alone)
Study: 2124180
Drug: Norethisterone enantate
Normalized name: Norethisterone enantate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norethisterone enantate 50 mg with estradiol valerate 5 mg (monthly injectable contraceptive)
Study: 6153846
Drug: Oral tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tetracycline hydrochloride (Amphocycline)
Study: 6153846
Drug: Oral tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tetracycline hydrochloride with 10% ethyl lactate solution applied twice daily
Study: 6153846
Drug: Local application
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local application of ethyl lactate solution only
Study: 31132664
Drug: Glatiramer acetate
Normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glatiramer acetate 40 mg/mL three times weekly (GA40)
Study: 25929558
Drug: Guardian Laryngeal
Normalized name: Giardia lamblia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guardian Laryngeal Mask Airway (G‐LMA)
Study: 21410839
Drug: MTZ in
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTZ in situ gel (0.8% metronidazole), applied twice daily for 5 days
Study: 21410839
Drug: Conventional vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional vaginal gel product, applied twice daily for 5 days
Study: 19561037
Drug: Dexamethasone (12‐16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (12‐16 mg i.v. on day 1, 8 mg i.v. on day 2, and 4‐8 mg i.v. on day 3)
Study: 17602038
Drug: 4.5 mg
Normalized name: phenol 14.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5 mg intrathecal bupivacaine
Study: 17602038
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg intrathecal bupivacaine
Study: 15106360
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human follicle stimulating hormone (rhFSH) (Gonal‐F, Serono)
Study: 11528569
Drug: Oral azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral azithromycin (1 g given weekly)
Study: 11528569
Drug: Benzathine penicillin
Normalized name: Benzathine penicillin G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzathine penicillin G (1.2 million U)
Study: 3277450
Drug: Mutual‐help group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mutual‐help group treatment led by nonclinicians
Study: 3277450
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Brief dynamic psychotherapy and Mutual-help group treatment)
Study: 28363636
Drug: DSM265 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: DSM265 (150 mg)
Study: 28363636
Drug: Mefloquine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine (10 mg/kg)
Study: 26431662
Drug: 10mg adefovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg adefovir dipivoxil capsules once daily
Study: 26431662
Drug: 10mg adefovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg adefovir dipivoxil capsules once daily + 5 million U Recombinant Human Interferon α‐2b every other day
Study: 26431662
Drug: 10mg adefovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg adefovir dipivoxil capsules once daily (control group)
Study: 19648681
Drug: CPT before
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT before BiPAP treatment
Study: 19648681
Drug: BiPAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: BiPAP treatment after conventional anti-infection, phlegm treatment and support treatment
Study: 17455407
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml isotonic normal saline (Control)
Study: 12414877
Drug: QUICKI (quantitative
Approvals — FDA: no, EMA: no, PMDA: no
Description: QUICKI (quantitative insulin sensitivity check index)
Study: 12414877
Drug: Insulin resistance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin resistance measured by HOMA
Study: 9809097
Drug: All solutions
Normalized name: ALCOHOL 0.57 mL in 1 mL / IODINE 0.06 g in 1 mL / POTASSIUM IODIDE 0.05 g in 1 mL / BORIC ACID 0.01 g in 1 mL / SODIUM BORATE 0.002 g in 1 mL TOPICAL LINIMENT [Ball Solutions]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All solutions at 50 vol.%
Study: 2676967
Drug: Desipramine (DMI)
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desipramine (DMI) at an average maximal daily dose of 4.6 +/- 0.2 mg/kg
Study: 365323
Drug: Levamisole (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (50 mg three times a day)
Study: 28675067
Drug: Neoadjuvant temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Neoadjuvant temozolomide (NeoTMZ) 200 mg/m2 days 1-5 every 28 days followed by RT 60 Gy in 30 fractions
Study: 22019520
Drug: TG4010 plus
Normalized name: TG4010
DrugBank: TG4010 (DB06584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TG4010 plus chemotherapy (cisplatin 75 mg/m² on day 1 and gemcitabine 1250 mg/m² on days 1 and 8, repeated every 3 weeks for up to six cycles)
Study: 22019520
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (cisplatin 75 mg/m² on day 1 and gemcitabine 1250 mg/m² on days 1 and 8, repeated every 3 weeks for up to six cycles)
Study: 17444589
Drug: Infliximab 3
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab 3 mg/kg plus MTX
Study: 17444589
Drug: Infliximab 6
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab 6 mg/kg plus MTX
Study: 15361763
Drug: L-arginine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (10 micromol/min)
Study: 15361763
Drug: N-monomethyl-L-arginine (L-NMMA;
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-monomethyl-L-arginine (L-NMMA; 4 micromol/min)
Study: 12575372
Drug: Tracheitis Plaster
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tracheitis Plaster (TP) applied on acupoints Dingchuan, Dashu, Fengmen, Feishu and Xinshu at back along both sides of thoracic vertebrae 1‐6, treatment duration: 20 times.
Study: 12575372
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of Siqikang, treatment duration: 20 times.
Study: 3549096
Drug: Nasal spray
Normalized name: Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray (200 units daily)
Study: 3549096
Drug: Nasal spray
Normalized name: Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray (400 units daily)
Study: 3549096
Drug: Suppository (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suppository (300 units)
Study: 3549096
Drug: Parenteral route
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral route
Study: 31509844
Drug: Calcipotriol-betamethasone ointment
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcipotriol-betamethasone ointment
Study: 27473888
Drug: Radium-223 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radium-223 (50 kBq/kg every 4 weeks for up to six injections)
Study: 27473888
Drug: Any-grade treatment-emergent
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any-grade treatment-emergent adverse events
Study: 27473888
Drug: Grade 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grade 3 or worse treatment-related adverse events
Study: 23887199
Drug: Low-volume group
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-volume group (1 ml·kg·h of balanced Ringer's solution until the end of cystectomy and then 3 ml·kg·h until the end of surgery combined with preemptive norepinephrine infusion at an initial rate of 2 µg·kg·h)
Study: 23887199
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (6 ml·kg·h of balanced Ringer's solution throughout surgery)
Study: 23327960
Drug: Arsenic trioxide
Normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Arsenic trioxide combined with transcatheter arterial chemoembolization (TACE) - 10 mg arsenic trioxide by intravenous infusion for 5 hours per day, 3 days after TACE, repeated every 2 weeks for 3-4 cycles
Study: 19733912
Drug: Acute phase
Normalized name: Acute phase reactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute phase cognitive therapy (A‐CT)
Study: 9504514
Drug: Autologous bone-marrow
Normalized name: SUS SCROFA BONE MARROW
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous bone-marrow transplant (BMT) after preparation with cyclophosphamide and total-body irradiation
Study: 8061425
Drug: BMS 180549
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BMS 180549 (superparamagnetic iron oxide contrast agent)
Study: 2661065
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose cyclosporin A (CyA)
Study: 2661065
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose cyclosporin A (CyA)
Study: 2661065
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose cyclosporin A (CyA) with NSAIDs
Study: 780406
Drug: Specific injection
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific injection therapy
Study: 31236286
Drug: Hyoscine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine (1 week at 0.6 mg daily, 3 weeks at 0.9 mg daily)
Study: 31236286
Drug: Glycopyrrolate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate (1 week at 2 mg daily, 3 weeks at 3 mg daily)
Study: 29231337
Drug: Balance acupuncture
Normalized name: Rebalance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balance acupuncture at Toutongxue point, treatment for 4 weeks, once a day, 5 times a week.
Study: 29231337
Drug: Sham acupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham acupuncture at a control point (3, 4 metatarsal combination), treatment for 4 weeks, once a day, 5 times a week.
Study: 23322818
Drug: MHT (Menopausal
Approvals — FDA: no, EMA: no, PMDA: no
Description: MHT (Menopausal Hormone Treatment)
Study: 16404492
Drug: High-impact exercise
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-impact exercise (acceleration levels exceeding 3.9 g)
Study: 16404492
Drug: High-impact exercise
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-impact exercise (acceleration levels exceeding 5.4 g)
Study: 16404492
Drug: Physical activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical activity at levels of 1.1-2.4 g
Study: 11244343
Drug: Hypotonic artificial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypotonic artificial tears, administered up to 6 times a day
Study: 11244343
Drug: Isotonic artificial
Normalized name: ISOTON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic artificial tears, administered up to 6 times a day
Study: 9256118
Drug: MOPP-ABVD with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOPP-ABVD with low-dose total-nodal irradiation (TNI)
Study: 9256118
Drug: MOPP-ABVD only
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOPP-ABVD only (chemotherapy-only group)
Study: 8509099
Drug: Cryotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryotherapy plus subcutaneously administered interferon alpha‐2a
Study: 10462244
Drug: Inactivated polio
Normalized name: Inactivated polio vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated polio vaccine (IPV)
Study: 24286534
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg Polaprezinc (PZ) enema
Study: 12848770
Drug: Fluticasone/Salmeterol (FP/SM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone/Salmeterol (FP/SM) 125 microg/SM 25 microg, 1 puff twice daily for 3 weeks
Study: 2938688
Drug: Arginine aspartate
Normalized name: Arginine aspartate
DrugBank: Arginine aspartate (DB15993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arginine aspartate 37.5 g
Study: 29530622
Drug: Capsaicin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsaicin (2 mg)
Study: 23054576
Drug: Bioenterics Intragastric
Normalized name: ALCOHOL 80 mL in 100 mL INTRAGASTRIC LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioenterics Intragastric Balloon (BIB) - saline-filled (500 ml saline + 10 ml methylene blue)
Study: 23054576
Drug: Endobag-Heliosphere -
Normalized name: Fluzone 2025 Southern Hemisphere
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endobag-Heliosphere - air-filled (950 ml air)
Study: 19855926
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg ibandronate given intravenously once every 3 months
Study: 19855926
Drug: 70 mg
Normalized name: silybin 70 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 mg alendronate given orally once per week
Study: 15251160
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg ibandronate
Study: 19855926
Drug: 70 mg
Normalized name: silybin 70 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 mg alendronate
Study: 15339678
Drug: Gemtuzumab ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Gemtuzumab ozogamicin (GO) 9 mg/m2 infused intravenously on days 1 and 15 followed by conventional chemotherapy (MICE regimen: mitoxantrone, cytarabine, etoposide)
Study: 10791297
Drug: Metrifonate (MTF)
Normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metrifonate (MTF) 2.9 mg/kg weekly for 6 months
Study: 10791297
Drug: Metrifonate (MTF)
Normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metrifonate (MTF) daily to achieve RBC AChE inhibition levels of 85.90%
Study: 8449581
Drug: Recombinant HB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant HB vaccine (Engerix‐B, 20 micrograms) given to 40 susceptible health-care workers within three days of exposure (Group B)
Study: 8449581
Drug: A single
Normalized name: Hemoccult Sensa Single Slide
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of HBIg (0.06 mg/kg) administered intramuscularly within three days of exposure followed by the first dose of vaccine (20 micrograms) (Group A)
Study: 3092933
Drug: Acupuncture after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture after premedication with 100 mg meptazinol (first study)
Study: 3092933
Drug: Acupuncture with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture with 10 mg nalbuphine (second study)
Study: 25866234
Drug: EtG immunoassay
Approvals — FDA: no, EMA: no, PMDA: no
Description: EtG immunoassay cutoff levels at 100 ng/ml
Study: 25866234
Drug: EtG immunoassay
Approvals — FDA: no, EMA: no, PMDA: no
Description: EtG immunoassay cutoff levels at 200 ng/ml
Study: 25866234
Drug: EtG immunoassay
Approvals — FDA: no, EMA: no, PMDA: no
Description: EtG immunoassay cutoff levels at 300 ng/ml
Study: 25866234
Drug: EtG immunoassay
Approvals — FDA: no, EMA: no, PMDA: no
Description: EtG immunoassay cutoff levels at 400 ng/ml
Study: 25866234
Drug: EtG immunoassay
Approvals — FDA: no, EMA: no, PMDA: no
Description: EtG immunoassay cutoff levels at 500 ng/ml
Study: 22936539
Drug: Four weekly
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four weekly multiprofessional senior group meetings including a follow-up home visit